At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 40 enrolled
Drug / intervention
Bevacizumab +1 moredrug
Likely dose
Bevacizumab 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Intranasal Bevacizumab for HHT-Related Epistaxis
In Brief
A Phase 4 clinical trial evaluating Bevacizumab and Placebo (Saline) for HHT and 4 related conditions. Completed, enrolled 40 participants across 1 site.
Detailed Summary
This is a randomized, controlled, double-blind, placebo-controlled trial of intranasal Avastin (bevacizumab) injection versus saline control for control of HHT-related epistaxis when used in conjunction with bipolar electrocautery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartAug 2014
First PostedMar 2015
Primary CompletionJan 2020
TodayJul 2026
First PostedMar 17, 2015
Enrollment StartAug 4, 2014
Primary CompletionJan 23, 2020
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 11.3 years ago
Interventions
Bevacizumabdrug
Bevacizumab will be mixed by the Stanford Hospital Pharmacy to a total dose of 100mg in 4mL, and 50mg (2mL) will be injected into each side of the nose
Placebo (Saline)drug
4mL of saline will be mixed by the Stanford Hospital Pharmacy as a control